Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. That translates to a net loss per share of $1.67 in the second quarter of 2018. Its net loss per share was $1.15 in the second quarter of 2017.
Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.
In September, there are 21 analysts covering Sarepta Therapeutics (SRPT) stock. Twenty of them have given the stock a “buy” or higher rating, and one has given it a “hold.” The mean rating for Sarepta stock is 1.71 with a target price of $188.58, implying an upside potential of 26.2% over its trading price of $149.44 on September 12.
Amid the broader market turmoil, Sarepta stock corrected from $124.05 on January 2 to $106.04 on April 25, which was also its lowest point in 2018. Subsequently, it climbed to $137.18 on July 25 and then sharply corrected to its current $120 level.
The enterprise value of Sarepta is $8.97 billion, and its enterprise-value-to-revenue ratio is 37.17x. Its price-to-sales ratio is 41.19x, and its price-to-book ratio is 14.20x.
Its current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 10.90x. In comparison, the ratios for peers Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), and BioCryst Pharmaceuticals (BCRX) are 13.20x, 8.40x, and 1.20x, respectively.